RTP Mobile Logo
Recent Advances and Real-World Implications in Medical Oncology: A Symposium in Partnership with the North Carolina Oncology Association and the South Carolina Oncology Society (Webinar Audio Proceedings)
Released March 2022

Proceedings from a daylong symposium held in partnership with the North Carolina Oncology Association and the South Carolina Oncology Society, featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elisabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar. Published March 4, 2022. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of cancer.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, lung and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing clinical trials in breast, gastrointestinal, genitourinary, lung and select hematologic cancers, and refer appropriate patients for study participation.
    • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer treatment algorithms in light of new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 7.25 (audio) and 6.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/NCOASCOSSummit22/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/NCOASCOSSummit22/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/NCOASCOSSummit22/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/NCOASCOSSummit22.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Virginia F Borges, MD, MMSc
    Professor of Medicine with Tenure
    Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research
    Deputy Head, Division of Medical Oncology
    Director, Breast Cancer Research Program and
    Young Women’s Breast Cancer Translational Program
    University of Colorado Cancer Center
    Aurora, Colorado

    Consulting Agreement: Seagen Inc; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Merck, Pfizer Inc, Seagen Inc.

    Natalie S Callander, MD
    Professor of Medicine
    Director, Myeloma Clinical Program
    Interim Director, Bone Marrow Transplant Program
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin

    No relevant conflicts of interest to disclose.

    Robert Dreicer, MD, MS
    Section Head, Medical Oncology
    Deputy Director, University of Virginia Comprehensive Cancer Center
    Associate Director for Clinical Research
    Professor of Medicine and Urology
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Hinova Pharmaceuticals Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Myovant Sciences, Pfizer Inc, Propella Therapeutics Inc, Seagen Inc, TavantaTherapeutics, Veru Inc; Consulting Agreements: Astellas, Pfizer Inc; Contracted Research: Arvinas, Exelixis Inc, Seagen Inc.

    Ian W Flinn, MD, PhD
    Director of Lymphoma Research Program
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements (to Sarah Cannon Research Institute): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Great Point Partners LLC, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Unum Therapeutics, Verastem Inc, Vincerx Pharma, YL-Pharma Co Ltd; Research Grants (to Sarah Cannon Research Institute): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc.

    Ramaswamy Govindan, MD
    Professor of Medicine
    Director, Section of Oncology
    Anheuser-Busch Endowed Chair in Medical Oncology
    Washington University School of Medicine
    St Louis, Missouri

    Advisory Committee: Jacobio Pharmaceuticals Group Co Ltd, Merck; Consulting Agreement: Inivata.

    Elisabeth I Heath, MD
    Associate Center Director, Translational Sciences
    Chair, Genitourinary Oncology Multidisciplinary Team
    Professor of Oncology and Medicine
    Hartmann Endowed Chair for Prostate Cancer Research
    Director, Prostate Cancer Research
    Karmanos Cancer Institute
    Wayne State University School of Medicine
    Detroit, Michigan

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Sanofi Genzyme; Consulting Agreement: Astellas; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Caris Life Sciences, Celgene Corporation, Celldex Therapeutics, Corcept Therapeutics, CureMeta, Dendreon Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Esanik Therapeutics Inc, Fortis Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Ignyta Inc, Inovio Pharmaceuticals Inc, Medivation Inc, a Pfizer Company, Merck, Merck Sharp & Dohme Corp, Oncolys BioPharma, Plexxikon Inc, Seagen Inc, Synta Pharmaceuticals Corp, Takeda Pharmaceuticals USA Inc, Tokai Pharmaceuticals Inc, Zenith Epigenetics; Honoraria: Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Seagen Inc; Speakers Bureau: Sanofi Genzyme.

    Howard S Hochster, MD
    Distinguished Professor of Medicine
    Rutgers Robert Wood Johnson Medical School
    Rutgers-CINJ Associate Director, Clinical Research
    Director, Clinical Oncology Research
    RWJBarnabas Health System
    New Brunswick, New Jersey

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Compass Therapeutics, Genentech, a member of the Roche Group, Merck, Processa Pharmaceuticals Inc; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Hutchison MediPharma, Mirati Therapeutics, Natera Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Ownership Interest: Elion Oncology Inc, TRIGR Therapeutics; Speakers Bureau: Natera Inc.

    Komal Jhaveri, MD
    Associate Attending Physician
    Breast Medicine Service and Early Drug Development Service
    Section Head, Endocrine Therapy Research Program
    Clinical Director, Early Drug Development Service
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    Assistant Professor of Medicine
    Weill Cornell College of Medicine
    New York, New York

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Lilly, Novartis, Pfizer Inc, Seagen Inc, Sun Pharma, Taiho Oncology Inc; Contracted Research: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Debiopharm, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, Novartis, Novita Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, VelosBio Inc, Zymeworks Inc.

    Melissa Johnson, MD
    Director, Lung Cancer Research Program
    Associate Director of Drug Development for the Drug Development Unit in Nashville
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements (All to Institution): AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Axelia Oncology, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Checkpoint Therapeutics Inc, CytomX Therapeutics, Daiichi Sankyo Inc, EcoR1 Capital LLC, Editas Medicine, Eisai Inc, EMD Serono Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gritstone Oncology, IDEAYA Biosciences, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics, Oncorus, Regeneron Pharmaceuticals Inc, Ribon Therapeutics, Sanofi Genzyme, Turning Point Therapeutics Inc, WindMIL Therapeutics; Contracted Research (All to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Atreca, BeiGene Ltd, BerGenBio ASA, BioAtla, Boehringer Ingelheim Pharmaceuticals Inc, Calithera Biosciences, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Dynavax, Elicio Therapeutics, EMD Serono Inc, Erasca, Genentech, a member of the Roche Group, Genmab, Genocea, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences Inc, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Kadmon, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, Memorial Sloan Kettering Cancer Center, Merck, Mirati Therapeutics, NeoImmuneTech, Neovia Oncology, Novartis, Numab, Nuvalent, OncoMed Pharmaceuticals Inc, Pfizer Inc, PMV Pharma, Rain Therapeutics, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi Genzyme, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, Silicon Therapeutics, Stemcentrx, Takeda Pharmaceuticals USA Inc, Tarveda Therapeutics, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics Inc, Tmunity Therapeutics Inc, Turning Point Therapeutics Inc, University of Michigan, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics Inc.

    Ann S LaCasce, MD, MMSc
    Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
    Associate Professor of Medicine, Harvard Medical School
    Lymphoma Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Wells A Messersmith, MD
    Chief Medical Officer, Cancer Center
    Associate Director of Clinical Services
    University of Colorado Cancer Center
    Aurora, Colorado

    Contracted Research: ALX Oncology, BeiGene Ltd, Bristol-Myers Squibb Company, Exelixis Inc, Experimental Drug Development Centre (Singapore), Immunomedics Inc, Pfizer Inc, Mitsubishi Tanabe Pharma America; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics, Zymeworks Inc.

    S Vincent Rajkumar, MD
    Edward W and Betty Knight Scripps Professor of Medicine
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Lilly, Merck, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, ​Seagen Inc, Puma Biotechnology Inc,​ Seagen Inc and Taiho Oncology Inc.

    Release date: March 2022
    Expiration date: March 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):